We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current INZY market cap is 287.24M. The company's latest EPS is USD -1.1521 and P/E is -4.04.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -16.91M | -19.53M | -18.37M | -16.39M | -18.07M |
| Net Income | -16.37M | -18.54M | -17.4M | -15.58M | -16.64M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -20.81M | -57.04M | -56.65M | -68.68M | -75.65M |
| Net Income | -19.72M | -56.42M | -56.62M | -67.06M | -71.17M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 154.02M | 139.2M | 141.8M | 150.93M | 205.7M |
| Total Liabilities | 19.24M | 20.8M | 38.45M | 45.34M | 45.49M |
| Total Equity | 134.78M | 118.39M | 103.35M | 105.59M | 160.21M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 47.94M | 169.36M | 123.54M | 139.2M | 200.85M |
| Total Liabilities | 81.16M | 11.26M | 14.27M | 20.8M | 60.37M |
| Total Equity | -33.22M | 158.1M | 109.27M | 118.39M | 140.48M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -43.36M | -57.76M | -17.77M | -33.32M | -52.19M |
| Investing | -8.62M | -5.4M | 13.77M | -2.56M | -47.18M |
| Financing | 72.79M | 72.79M | 20.1M | 43.74M | 113.45M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -18.81M | -35.97M | -48.15M | -57.76M | -70.68M |
| Investing | -8.39M | -117.18M | 42.8M | -5.4M | -53.65M |
| Financing | 22.97M | 149.81M | 609k | 72.79M | 125.97M |
| Market Cap | 287.24M |
| Price to Earnings Ratio | -4.04 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 8.32 |
| Price to Book Ratio | 2.05 |
| Dividend Yield | - |
| Shares Outstanding | 61.77M |
| Average Volume (1 week) | 561.49k |
| Average Volume (1 Month) | 773.3k |
| 52 Week Change | -17.55% |
| 52 Week High | 7.795 |
| 52 Week Low | 2.689 |
| Spread (Intraday) | 0.74 (15.58%) |
| Company Name | Inozyme Pharma Inc |
| Address |
corporation trust center 1209 orange st wilmington, delaware 19801 |
| Website | https://www.inozyme.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
